Opiate use after total hip arthroplasty for metastatic bone disease





total hip arthroplasty, metastatic bone disease, opioid, oncology


Objectives: To investigate post-operative opioid use following a total hip arthroplasty (THA) in metastatic bone disease (MBD) patients and identify factors associated with post-operative opioid use at 6 weeks and 90 days.

Background: MBD commonly affects the hip, and surgical intervention including THA may be indicated for pain relief or to improve function. Following THA, patients are often prescribed short courses of opioids for post-operative pain relief. No study has evaluated opiate use following THA in patients for MBD.

Methods: This was a retrospective review of patients using opioids preoperatively who underwent primary THA for MBD at two institutions between 2009 and 2022. Preoperative and post-operative opioid usages, respectively, at 6 weeks and 90 days were quantified through calculating daily morphine milligram equivalents (MMEs) and compared using the sign test. Factors associated with post-operative opioid use at 6 weeks and 90 days were compared using χ2 test or Fisher's exact test as appropriate.

Results: Nineteen THA and 11 THA with complex acetabular reconstruction were included. At 6 weeks, 26 (86.7 percent) patients were utilizing opiates, and at 90 days, 23 (76.7 percent) patients were utilizing opiates. There was a statistically significant difference between median daily preoperative MME compared to daily MME at 90 days (p < 0.001). The only statistically significant association with opioid use at 90 days was opioid use at 6 weeks.

Conclusion: To our knowledge, this is the first paper evaluating post-operative opioid use following primary THA in MBD patients. After THA in the setting of MBD, patients exhibit decreased post-operative opioid use. Future studies with larger cohorts should be conducted to characterize post-operative opioid use following joint arthroplasty in MBD patients.

Author Biographies

Gayathri Vijayakumar, BS

Department of Orthopedic Surgery, Section of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois

Dylan Vance, BS

University of Kansas Medical Center, Kansas City, Kansas

Matthew W. Colman, MD

Department of Orthopedic Surgery, Section of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois

Steven Gitelis, MD

Department of Orthopedic Surgery, Section of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois

Kyle Sweeney, MD

University of Kansas Medical Center, Kansas City, Kansas

Alan T. Blank, MD, MS

Department of Orthopedic Surgery, Section of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois


Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 Pt 2): 6243s-6249s. DOI: 10.1158/1078-0432.CCR-06-0931.

Tsukamoto S, Kido A, Tanaka Y, et al.: Current overview of treatment for metastatic bone disease. Curr Oncol Tor Ont. 2021; 28(5): 3347-3372. DOI: 10.3390/curroncol28050290.

Toma CD, Dominkus M, Nedelcu T, et al.: Metastatic bone disease: A 36-year single centre trend-analysis of patients admitted to a tertiary orthopaedic surgical department. J Surg Oncol. 2007; 96(5): 404-410. DOI: 10.1002/jso.20787.

Hage WD, Aboulafia AJ, Aboulafia DM: Incidence, location, and diagnostic evaluation of metastatic bone disease. Orthop Clin North Am. 2000; 31(4): 515-528. DOI: 10.1016/S0030-5898(05)70171-1.

Picci P, Manfrini M, Fabbri N, et al.: Atlas of Musculoskeletal Tumors and Tumorlike Lesions: The Rizzoli Case Archive. Berlin: Springer Science & Business Medi, 2014.

Migliorini F, Maffulli N, Trivellas A, et al.: Bone metastases: A comprehensive review of the literature. Mol Biol Rep. 2020; 47(8): 6337-6345. DOI: 10.1007/s11033-020-05684-0.

Issack PS, Kotwal SY, Lane JM: Management of metastatic bone disease of the acetabulum. J Am Acad Orthop Surg. 2013; 21(11): 685-695. DOI: 10.5435/JAAOS-21-11-685.

Portenoy RK: Treatment of cancer pain. The Lancet. 2011; 377(9784): 2236-2247. DOI: 10.1016/S0140-6736(11)60236-5.

Janjan NA, Payne R, Gillis T, et al.: Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symp Manag. 1998; 16(3): 171-178. DOI: 10.1016/s0885-3924(98)00069-4.

Jacofsky DJ, Haidukewych GJ: Management of pathologic fractures of the proximal femur: State of the art. J Orthop Trauma. 2004; 18(7): 459-469. DOI: 10.1097/00005131-200408000-00013.

Harrington KD: Orthopedic surgical management of skeletal complications of malignancy. Cancer. 1997; 80(S8): 1614-1627. DOI: 10.1002/(SICI)1097-0142(19971015)80:8+<1614::AIDCNCR12>3.0.CO;2-2.

Issack PS, Barker J, Baker M, et al.: Surgical management of metastatic disease of the proximal part of the femur. J Bone Joint Surg Am. 2014; 96(24): 2091-2098. DOI: 10.2106/JBJS.N.00083.

Steensma M, Boland PJ, Morris CD, et al.: Endoprosthetic treatment is more durable for pathologic proximal femur fractures. Clin Orthop. 2012; 470(3): 920-926. DOI: 10.1007/s11999-011-2047-z.

Harvey N, Ahlmann ER, Allison DC, et al.: Endoprostheses last longer than intramedullary devices in proximal femur metastases. Clin Orthop. 2012; 470(3): 684-691. DOI: 10.1007/s11999-011-2038-0.

Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27(3): 165-176. DOI: 10.1053/ctrv.2000.0210.

Tan TL, Rondon AJ, Wilt Z, et al.: Understanding opioid use after total hip arthroplasty: A comprehensive analysis of a mandatory prescription drug monitoring program. J Am Acad Orthop Surg. 2020; 28(20): e917-e922. DOI: 10.5435/JAAOS-D-19-00676.

Bedard NA, Pugely AJ, Dowdle SB, et al.: Opioid use following total hip arthroplasty: Trends and risk factors for prolonged use. J Arthroplast. 2017; 32(12): 3675-3679. DOI: 10.1016/j.arth.2017.08.010.

Cunningham DJ, Ryan SP, George SZ, et al.: Opioid legislation and narcotic filling in total hip arthroplasty: Descriptive study of time and state-level trends in the United States. Subst Abuse Treat Prev Policy. 2021; 16(1): 75. DOI: 10.1186/s13011-021-00410-w.

Mitera G, Zeiadin N, Kirou-Mauro A, et al.: Retrospective assessment of cancer pain management in an outpatient palliative radiotherapy clinic using the pain management index. J Pain Symptom Manage. 2010; 39(2): 259-267. DOI: 10.1016/j.jpainsymman.2009.07.005.

Kirou-Mauro AM, Hird A, Wong J, et al.: Has pain management in cancer patients with bone metastases improved? A seven-year review at an outpatient palliative radiotherapy clinic. J Pain Symptom Manage. 2009; 37(1): 77-84. DOI: 10.1016/j.jpainsymman.2007.12.014.

Vieira C, Fragoso M, Pereira D, et al.: Pain prevalence and treatment in patients with metastatic bone disease. Oncol Lett. 2019; 17(3): 3362-3370. DOI: 10.3892/ol.2019.10013.

van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, et al.: Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. J Pain Symptom Manage. 2016; 51(6): 1070-1090.e9. DOI: 10.1016/j.jpainsymman.2015.12.340.

Lee JSJ, Hu HM, Edelman AL, et al.: New persistent opioid use among patients with cancer after curative-intent surgery. J Clin Oncol. 2017; 35(36): 4042-4049. DOI: 10.1200/JCO.2017.74.1363.

Beauchemin MP, Raghunathan RR, Accordino MK, et al.: New persistent opioid use among adolescents and young adults with sarcoma. Cancer. 2022; 128(14): 2777-2785. DOI: 10.1002/cncr.34238.

Inacio MCS, Hansen C, Pratt NL, et al.: Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: A retrospective cohort study. BMJ Open. 2016; 6(4): e010664. DOI: 10.1136/bmjopen-2015-010664.

Rajamäki TJ, Puolakka PA, Hietaharju A, et al.: Use of prescription analgesic drugs before and after hip or knee replacement in patients with osteoarthritis. BMC Musculoskelet Disord. 2019; 20(1): 427. DOI: 10.1186/s12891-019-2809-4.

Zarling BJ, Yokhana SS, Herzog DT, et al.: Preoperative and postoperative opiate use by the arthroplasty patient. J Arthroplasty. 2016; 31(10): 2081-2084. DOI: 10.1016/j.arth.2016.03.061.

Von Korff M, Korff MV, Saunders K, et al.: De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008; 24(6): 521-527. DOI: 10.1097/AJP.0b013e318169d03b.

Dowell D, Ragan KR, Jones CM, et al.: CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep. 2022; 71(3): 1-95. DOI: 10.15585/mmwr.rr7103a1.

Shen C, Thornton JD, Newport K, et al.: Trends and patterns in the use of opioids among metastatic breast cancer patients. Sci Rep. 2020; 10(1): 21698. DOI: 10.1038/s41598-020-78569-8.

Bennett M, Paice JA, Wallace M: Pain and opioids in cancer care: Benefits, risks, and alternatives. Am Soc Clin Oncol Educ Book. 2017; 37: 705-713. DOI: 10.1200/EDBK_180469.

Koyyalagunta D, Bruera E, Aigner C, et al.: Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF. Pain Med. 2013; 14(5): 667-675. DOI: 10.1111/pme.12100.

Namba RS, Inacio MCS, Pratt NL, et al.: Postoperative opioid use as an early indication of total hip arthroplasty failure. Acta Orthop. 2016; 87(Suppl. 1): 37-43. DOI: 10.1080/17453674.2016.1181820.

Kunkel ST, Gregory JJ, Sabatino MJ, et al.: Does preoperative opioid consumption increase the risk of chronic postoperative opioid use after total joint arthroplasty? Arthroplasty Today. 2021; 10: 46-50. DOI: 10.1016/j.artd.2021.05.012.

Prentice HA, Inacio MCS, Singh A, et al.: Preoperative risk factors for opioid utilization after total hip arthroplasty. J Bone Joint Surg. 2019; 101(18): 1670-1678. DOI: 10.2106/JBJS.18.01005.

Singh JA, Lewallen D: Predictors of pain and use of pain medications following primary total hip arthroplasty (THA): 5,707 THAs at 2-years and 3,289 THAs at 5-years. BMC Musculoskelet Disord. 2010; 11: 90. DOI: 10.1186/1471-2474-11-90.

Chaudhary MA, Dalton MK, Koehlmoos TP, et al.: Identifying patterns and predictors of prescription opioid use after total joint arthroplasty. Mil Med. 2021; 186(5-6): 587-592. DOI: 10.1093/milmed/usaa573.

Hereford TE, Porter A, Stambough JB, et al.: Prevalence of chronic opioid use in the elderly after hip fracture surgery. J Arthroplasty. 2022; 37(7S): S530-S535. DOI: 10.1016/j.arth.2022.01.071.

Agarwalla A, Liu JN, Gowd AK, et al.: Differential use of narcotics in total hip arthroplasty: A comparative matched analysis between osteoarthritis and femoral neck fracture. J Arthroplasty. 2020; 35(2): 471-476. DOI: 10.1016/j.arth.2019.09.004.



How to Cite

Vijayakumar, G., D. Vance, M. W. Colman, S. Gitelis, K. Sweeney, and A. T. Blank. “Opiate Use After Total Hip Arthroplasty for Metastatic Bone Disease”. Journal of Opioid Management, vol. 19, no. 5, Nov. 2023, pp. 395-02, doi:10.5055/jom.0813.